Page URL:

New personalised treatment shrinks skin cancer tumours by 30 per cent

8 June 2009
Appeared in BioNews 511

A new 'personalised' drug has been found to decrease the size of tumours in patients with advanced melanoma by 30 per cent. Results of an initial trial were presented at the meeting of the American Society of Clinical Oncology in Orlando, US. The results showed that the experimental treatment, a 'personalised' oral drug known as PLX4032, kept the melanoma at bay for six months. Pharmaceutical giant Roche and a privately owned company called Plexxikon Inc will carry out larger trials later this year and undertake testing to select suitable patients as candidates for further trials and later for treatment with the drug.

'Malignant melanoma', or simply 'melanoma', is a skin tumour that involves pigment-producing skin cells. It is the most serious form of skin cancer, and one of the deadliest of all cancers. Each year in the UK some 2,000 people die from melanomas and around 10,400 people are diagnosed with the condition - roughly fourfold the number diagnosed in the 1970s - making it the most rapidly increasing cancer in the UK. Melanomas start as a blemish or change to a mole on the skin and are treatable if caught early enough.

However, once patients develop metastatic disease (where the cancer spreads to other organs such as the lungs or liver) there are few treatment options and only five per cent of patients live five years beyond diagnosis - most die within a matter of months. In the trial nine of the 16 cancer patients saw their tumours shrink by at least 30 per cent and survival without disease progression was extended. When asked what difference the drug made, one doctor involved in the trial commented that it was the first time he had 'time to get to know my patients'.

A genetic mutation in the 'BRAF' cellular pathway, an important mediator of cell growth and division, occurs in 60 per cent of melanomas and about eight per cent of all solid tumours. The new drug (and its competitors, including XL281 from Exelixis Inc and RAF265 from Novartis AG) works by selectively targeting and destroying tumour cells that carry this BRAF mutation. PLX4032 is also being developed to help fight other cancers, such as bowel cancer, but has no effect against cancers that lack the BRAF mutation. New drugs such as these are seen by many to signal the end of 'blockbuster' drugs that treat everybody or every cancer, in favour of treatments that are tailored to the genetic makeup of specific cancers or groups of individuals.

The trial's lead investigator Dr Keith Flaherty, an assistant professor at the Abramson Cancer Centre of the University of Pennsylvania, said: 'Seven years after BRAF mutations were first identified, we have validation that this mutation is a cancer driver and therapeutic target. In addition to a new and important chapter in the story of targeted therapy development in cancer, we are especially excited for our melanoma patients for whom there are few treatment options.'

Scientists hail the first effective treatment for skin cancer victims
The Independent |  2 June 2009
Skin cancer drug uses genetics |  3 June 2009
Targeted drug shows promise against melanoma-study
The Guardian |  1 June 2009
5 November 2012 - by Maria Sheppard 
A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...
28 May 2012 - by James Brooks 
A drug that mimics broken strands of DNA and pushes treatment-resistant cancer cells to autodestruct has produced encouraging results in a first clinical trial. The medicine, DT01, is the forerunner for a new class of drug developed by researchers at the Institut Curie in Paris...
28 September 2009 - by Lorna Stewart 
An early stage trial of a new drug has given hope to skin cancer patients. The phase I trial, the results of which were presented at the European Cancer Organisation and the European Society for Medical Oncology conferences in Berlin, tested the drug PLX4032 for the treatment of advanced metastatic melanoma....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.